122 related articles for article (PubMed ID: 32547702)
1. HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells.
Mahmud H; Mendez M; Mukhopadhyay B; Holter-Chakrabarty J; Ghosh AK
Oncotarget; 2020 Jun; 11(22):2037-2046. PubMed ID: 32547702
[TBL] [Abstract][Full Text] [Related]
2. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
[TBL] [Abstract][Full Text] [Related]
3. B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.
Schmid VK; Hobeika E
Front Oncol; 2024; 14():1339620. PubMed ID: 38469232
[TBL] [Abstract][Full Text] [Related]
4. Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
Kakodkar P; More S; András K; Papakonstantinou N; Kelly S; Makrooni MA; Ortutay C; Szegezdi E
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664705
[TBL] [Abstract][Full Text] [Related]
5. LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells.
Talab F; Allen JC; Thompson V; Lin K; Slupsky JR
Mol Cancer Res; 2013 May; 11(5):541-54. PubMed ID: 23505068
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.
Negro R; Gobessi S; Longo PG; He Y; Zhang ZY; Laurenti L; Efremov DG
Blood; 2012 Jun; 119(26):6278-87. PubMed ID: 22569400
[TBL] [Abstract][Full Text] [Related]
9. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
10. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
Ji TT; Chen QN; Tao SD; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
[TBL] [Abstract][Full Text] [Related]
11. Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival.
Wang YH; Fan L; Wang L; Zhang R; Zou ZJ; Fang C; Zhang LN; Li JY; Xu W
Leuk Lymphoma; 2013 Jun; 54(6):1165-70. PubMed ID: 23039362
[TBL] [Abstract][Full Text] [Related]
12. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
13. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.
Suljagic M; Laurenti L; Tarnani M; Alam M; Malek SN; Efremov DG
Leukemia; 2010 Dec; 24(12):2063-71. PubMed ID: 20861921
[TBL] [Abstract][Full Text] [Related]
15. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells.
Semichon M; Merle-Béral H; Lang V; Bismuth G
Leukemia; 1997 Nov; 11(11):1921-8. PubMed ID: 9369427
[TBL] [Abstract][Full Text] [Related]
16. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.
Kawauchi K; Ogasawara T; Yasuyama M
Int J Hematol; 2002 Jun; 75(5):508-13. PubMed ID: 12095152
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
18. B cell receptor signaling down-regulates forkhead box transcription factor class O 1 mRNA expression via phosphatidylinositol 3-kinase and Bruton's tyrosine kinase.
Hinman RM; Bushanam JN; Nichols WA; Satterthwaite AB
J Immunol; 2007 Jan; 178(2):740-7. PubMed ID: 17202334
[TBL] [Abstract][Full Text] [Related]
19. Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.
Efremov DG; Wiestner A; Laurenti L
Mediterr J Hematol Infect Dis; 2012; 4(1):e2012067. PubMed ID: 23170196
[TBL] [Abstract][Full Text] [Related]
20. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
Slinger E; Thijssen R; Kater AP; Eldering E
Leukemia; 2017 Dec; 31(12):2601-2607. PubMed ID: 28462919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
